Literature DB >> 18445838

Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer.

Angela Katz1, Barbara L Smith, Mehra Golshan, Andrzej Niemierko, Wendy Kobayashi, Rita Abi Raad, Alexandra Kelada, Levi Rizk, Julia S Wong, Jennifer R Bellon, Michele Gadd, Michelle Specht, Alphonse G Taghian.   

Abstract

PURPOSE: The standard of care for patients with a positive (+) sentinel lymph node (SLN) is axillary dissection; however, for various reasons, some SLN+ patients do not undergo dissection. The purpose of this study was to define possible predictors of having four or more involved nodes to provide information for clinicians and patients making decisions about adjuvant chemotherapy and radiation. PATIENTS AND METHODS: We reviewed the records of 402 patients with invasive breast cancer and one to three involved SLNs who underwent completion axillary dissection at two academic cancer centers. None of these patients received neoadjuvant chemotherapy. Factors associated with having four or more involved axillary nodes (SLNs and non-SLNs) were evaluated by univariate and multivariate logistic regression analysis.
RESULTS: Eighty-seven patients had four or more positive nodes. On multivariate analysis, having four or more SLNs was associated with tumor histology, primary tumor size, lymphovascular space invasion, extranodal extension, the number of involved SLNs, the number of uninvolved SLNs, and the size of the largest SLN metastasis. A nomogram to predict the probability of having four or more nodes based on patients' pathologic data was developed from the multivariate logistic regression model. A separate previously published data set of 206 SLN+ patients treated at a community hospital in another city was used to validate this model.
CONCLUSION: Patients with a low probability of having four or more nodes can be identified from known pathologic features. The nomogram developed will be helpful to clinicians making adjuvant treatment recommendations.

Entities:  

Mesh:

Year:  2008        PMID: 18445838     DOI: 10.1200/JCO.2007.11.9479

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Is Completion Axillary Dissection Necessary for This Patient?

Authors:  Sadullah Girgin; Atilla Soran; Nilüfer Güler; Maktav Dinçer; Gökhan Demir
Journal:  J Breast Health       Date:  2014-07-01

Review 2.  Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Arch Pathol Lab Med       Date:  2016-08       Impact factor: 5.534

3.  Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy.

Authors:  Christopher Loiselle; Peter R Eby; Janice N Kim; Kristine E Calhoun; Kimberly H Allison; Vijayakrishna K Gadi; Sue Peacock; Barry E Storer; David A Mankoff; Savannah C Partridge; Constance D Lehman
Journal:  Acad Radiol       Date:  2014-01       Impact factor: 3.173

4.  Predicting four or more metastatic axillary lymph nodes in patients with sentinel node-positive breast cancer: assessment of existent risk scores.

Authors:  Benjamin Zendejas; Tanya L Hoskin; Amy C Degnim; Carol A Reynolds; David R Farley; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2010-04-29       Impact factor: 5.344

Review 5.  Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy.

Authors:  Agnès Tallet; Eric Lambaudie; Monique Cohen; Mathieu Minsat; Marie Bannier; Michel Resbeut; Gilles Houvenaeghel
Journal:  World J Clin Oncol       Date:  2016-04-10

6.  Evaluation of the Probability of Non-sentinel Lymph Node Metastasis in Breast Cancer Patients with Sentinel Lymph Node Metastasis using Two Different Methods.

Authors:  İrfan Başoğlu; Muhammet Ferhat Çelik; Ahmet Cem Dural; Mustafa Gökhan Ünsal; Cevher Akarsu; Halil Fırat Baytekin; Selin Kapan; Halil Alış
Journal:  J Breast Health       Date:  2015-10-01

7.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Authors:  Mila Donker; Geertjan van Tienhoven; Marieke E Straver; Philip Meijnen; Cornelis J H van de Velde; Robert E Mansel; Luigi Cataliotti; A Helen Westenberg; Jean H G Klinkenbijl; Lorenzo Orzalesi; Willem H Bouma; Huub C J van der Mijle; Grard A P Nieuwenhuijzen; Sanne C Veltkamp; Leen Slaets; Nicole J Duez; Peter W de Graaf; Thijs van Dalen; Andreas Marinelli; Herman Rijna; Marko Snoj; Nigel J Bundred; Jos W S Merkus; Yazid Belkacemi; Patrick Petignat; Dominic A X Schinagl; Corneel Coens; Carlo G M Messina; Jan Bogaerts; Emiel J T Rutgers
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

8.  Assessment of hospital-level adjusted breast cancer sentinel lymph node positivity rates.

Authors:  Elizabeth R Berger; Karl Y Bilimoria; Christine V Kinnier; Christina A Minami; Kevin P Bethke; Nora M Hansen; Ryan P Merkow; David P Winchester; Anthony D Yang
Journal:  J Surg Oncol       Date:  2018-11-27       Impact factor: 3.454

9.  Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles.

Authors:  Masahiro Sugimoto; David T Wong; Akiyoshi Hirayama; Tomoyoshi Soga; Masaru Tomita
Journal:  Metabolomics       Date:  2009-09-10       Impact factor: 4.290

10.  Predicting Non-sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population with 1-2 Positive Sentinel Nodes: Development and Assessment of a New Predictive Nomogram.

Authors:  Jia-ying Chen; Jia-jian Chen; Jing-yan Xue; Ying Chen; Guang-yu Liu; Qi-xia Han; Wen-tao Yang; Zhen-zhou Shen; Zhi-min Shao; Jiong Wu
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.